rs12447924 — CETP

CETP rs12447924 — The HDL Haplotype Gatekeeper

Cholesteryl ester transfer protein (CETP) is the molecular shuttle that remodels your lipoprotein particles. Operating in blood plasma, it exchanges cholesteryl esters¹¹ cholesteryl esters
lipid molecules in which cholesterol is esterified with a fatty acid — the main cargo form of cholesterol inside lipoprotein particles from HDL particles for triglycerides from VLDL and LDL. The net effect: each CETP transaction depletes HDL of cholesterol and returns that cholesterol to the atherogenic lipoprotein pool. More CETP activity means lower HDL-C; less activity means higher HDL-C.

rs12447924 is a C/T variant located approximately 1,700 bases upstream of the CETP transcription start site, within the gene's promoter region. It sits in a tightly linked haplotype block along with rs3764261 (−2568), the GWAS lead SNP for this region, and rs4783961 (−998), three tagSNPs in strong linkage disequilibrium (D′=0.92–0.97) that collectively mark one of the most replicated HDL-cholesterol loci in the human genome. The T allele at rs12447924 is part of the HDL-raising 'ATAA' promoter haplotype; the C allele marks the HDL-lowering 'CTAG' haplotype.

The Mechanism

Upstream variants in this haplotype block regulate CETP transcription in the liver. The HDL-raising haplotype — tagged by the T allele at rs12447924 — is associated with reduced CETP gene expression and lower plasma CETP activity. With less CETP protein secreted, the rate of cholesteryl ester transfer from HDL to VLDL slows, allowing HDL particles to retain more of their cholesterol cargo and circulate at higher concentrations.

The promoter haplotype containing the C allele at rs12447924 is associated with normal-to-higher CETP expression, maintaining the full cholesterol transfer rate and producing lower circulating HDL-C. Mechanistic studies examining adjacent upstream variants (rs247616, in near-complete LD with this block) confirm that these upstream elements act as transcriptional enhancers in hepatocytes: the minor-frequency variants reduce luciferase reporter activity by approximately 1.7-fold in HepG2 cells²² 1.7-fold in HepG2 cells
Chasidah Oommen et al., Regulation of CETP expression by upstream polymorphisms, Atherosclerosis 2015. This directly links the promoter haplotype to the amount of CETP protein produced, not just its enzymatic activity per molecule.

The Evidence

The most detailed genotype-level data for rs12447924 comes from the Sikh Diabetes Study³³ Sikh Diabetes Study
Wander et al., n=2,431 individuals stratified by glycemic status, where haplotype analysis showed the ATAA haplotype (T allele at rs12447924) associated with +2.71 mg/dL higher HDL-C (p=6.38×10⁻⁵) in normoglycemic individuals, and the CTAG haplotype (C allele at rs12447924) associated with −1.78 mg/dL lower HDL-C (p=0.025).

Because rs12447924 is in strong LD with the GWAS lead SNPs for this region, studies of those neighboring variants provide the broadest evidence base. The Women's Health Study⁴⁴ Women's Health Study
Ridker et al., n=18,245, average 10-year follow-up found that CETP haplotype variants in this block were associated with 3.1 mg/dL higher HDL-C and a 24% lower risk of myocardial infarction (HR 0.76, 95% CI 0.62–0.94). A genome-wide meta-analysis of statin response⁵⁵ genome-wide meta-analysis of statin response
Postmus et al., n=27,720 found the CETP locus to be the only genome-wide significant predictor of HDL-C increase during statin treatment, with the HDL-raising haplotype predicting a greater HDL response to statins.

The gene-diet interaction evidence is clinically meaningful. In the combined POUNDS LOST and DIRECT randomized trials⁶⁶ POUNDS LOST and DIRECT randomized trials
Ma et al., n=894 total, individuals carrying the CETP upstream haplotype in the HDL-lowering direction showed significantly smaller HDL-C improvements on low-fat diets compared to high-fat diets (11.7 vs 4.5% increase, p<0.001). The SNAP trial⁷⁷ SNAP trial
Economos et al., n=524 young adults further showed that the HDL-lowering CETP genotype predicted declining HDL-C over time in the untreated control arm, but this trajectory was eliminated in the lifestyle intervention arm — demonstrating that the genetic disadvantage is modifiable.

Practical Actions

For TT homozygotes (~58% of Europeans): your CETP promoter is biased toward the HDL-raising haplotype. HDL-C levels are expected to be in the upper range for your demographic. Standard lipid monitoring applies.

For CT heterozygotes (~36% of Europeans): one C allele places you in an intermediate position. HDL-C may trend slightly lower than TT individuals. Limiting saturated fat intake and maintaining a healthy omega-3 to omega-6 ratio preserves your HDL level.

For CC homozygotes (~6% of Europeans): two C alleles orient your CETP promoter toward full expression and maximum cholesteryl ester transfer rate. HDL-C is expected to be below-average. The gene-diet evidence specifically supports choosing higher dietary fat quality (replacing saturated fat with polyunsaturated fats) over a low-fat approach when managing HDL. Checking both HDL-C and ApoA-I gives a more complete cardiovascular picture than HDL-C alone.

Interactions

rs12447924 is in strong linkage disequilibrium (D′=0.92–0.97) with rs3764261, the GWAS lead SNP for the CETP upstream haplotype block, and with rs247616, the variant most directly implicated in transcriptional regulation. Genetic tests may report any of these three; they largely tag the same underlying haplotype effect. rs708272 (TaqIB, intron 1) is in the same gene but a different LD block — it adds independent HDL-C variance on top of the upstream haplotype.

The LIPC rs1532085 variant also modulates HDL-C levels through hepatic lipase activity rather than CETP-mediated transfer. When both a CETP upstream C-allele genotype and a LIPC A-allele genotype co-occur, the two mechanisms partially counteract each other: reduced CETP activity (LIPC A allele, fewer transfers) tends to raise HDL, while the CETP C-allele haplotype tends to lower it. The net HDL-C level depends on which effect predominates, and particle-level testing (NMR lipoprofile) is more informative than total HDL-C in individuals carrying both variants.